Amarin (AMRN)
(Delayed Data from NSDQ)
$0.61 USD
-0.01 (-1.06%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $0.61 0.00 (-0.72%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 221 - 240 ( 365 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2018 Ought to Mark End of a Long Journey (or a New Beginning); Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
3Q Update: Getting Our Ducks in a Row Ahead of REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
We Believe There Is Now an Attractive Entry Point Heading Into Interim Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
CANTOS Study Further Validates Mechanism and Commercial Upside to REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Historical Rx Review Suggests Limited Downside to Vascepa Underlying Revenue From Potential REDUCE-IT Miss
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
1Q Update: Events Tracking to Expectation, Focus Remains on REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Continued Uptick in Vascepa Scripts to Support a Cash Flow Positive 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
REDUCE-IT Stays on the Right Side of the Track: 1Q16 Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Promotion of ANCHOR May Give Early Peek at Market for REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
How Much Is Off-label Promotion into a 10x Market Worth?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
REDUCE-IT Revisited: Upgrading to a Buy Rating and raising PT to $10
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.